Hemgn (a gene symbol for hemogen in mouse, EDAG in human and RP59 in rat) encodes a nuclear protein that is highly expressed in hematopoietic tissues and acute leukemia. To characterize its regulatory mechanisms, we examined the activities of a Hemgn promoter containing 2975 bp of 5 0 flanking sequence and 196 bp of 5 0 untranslated region (5 0 UTR) sequence both in vitro and in vivo: this promoter is preferentially activated in a hematopoietic cell line, not in nonhematopoietic cell lines, and is sufficient to drive the transcription of a lacZ transgene in hematopoietic tissues in transgenic mice. Mutagenesis analyses showed that the 5 0 UTR including two highly conserved GATA boxes is critical for the promoter activity. GATA1, not GATA2, binds to the GATA binding sites and transactivates the Hemgn promoter in a dose-dependent manner. Furthermore, the expression of human hemogen (EDAG) transcripts were closely correlated with levels of GATA1 transcripts in primary acute myeloid leukemia specimens. This study suggests that the Hemgn promoter contains critical regulatory elements for its transcription in hematopoietic tissues and Hemgn is a direct target of GATA1 in leukemia cells.
Hemgn (a gene symbol for hemogen in mouse, EDAG in human and RP59 in rat) encodes a nuclear protein that is highly expressed in hematopoietic tissues and acute leukemia. To characterize its regulatory mechanisms, we examined the activities of a Hemgn promoter containing 2975 bp of 5 0 flanking sequence and 196 bp of 5 0 untranslated region (5 0 UTR) sequence both in vitro and in vivo: this promoter is preferentially activated in a hematopoietic cell line, not in nonhematopoietic cell lines, and is sufficient to drive the transcription of a lacZ transgene in hematopoietic tissues in transgenic mice. Mutagenesis analyses showed that the 5 0 UTR including two highly conserved GATA boxes is critical for the promoter activity. GATA1, not GATA2, binds to the GATA binding sites and transactivates the Hemgn promoter in a dose-dependent manner. Furthermore, the expression of human hemogen (EDAG) transcripts were closely correlated with levels of GATA1 transcripts in primary acute myeloid leukemia specimens. This study suggests that the Hemgn promoter contains critical regulatory elements for its transcription in hematopoie
Introduction
Hemgn is highly expressed in the hematopoietic system. [1] [2] [3] The developmental expression pattern of Hemgn marks its hematopoietic ontogeny. In early embryogenesis, the expression of Hemgn is detected in blood islands of the yolk sac and in primitive blood. 1 In later development, the expression is sequentially localized in active hematopoietic sites, such as fetal liver and bone marrow. 1, 3 Among hematopoietic lineages, Hemgn is predominantly expressed in erythroid and megakaryocytic precursor cells; it is also expressed in hematopoietic stem cells and early progenitors. 1, 3 However, it is absent in matured lymphocytes. 1, 3 Just like Hemgn, the human hemogen orthologue (EDAG) exhibits specific expression in human hemotopoietic tissues and cells, including adult bone marrow and fetal liver. 1 However, no EDAG transcripts are detected in adult liver, heart, brain, skeletal muscle, kidney, spleen, pancreas, tonsil, colon and peripheral blood mononuclear cells. 2 EDAG is highly expressed in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and has been demonstrated to be involved in erythroleukemia differentiation, survival and apoptosis and cell transformation of NIH3T3 cells. 4, 5 ALL these studies suggest that overexpression of EDAG in acute leukemia may play an important role in leukemogensis. More recently, assocaition of overexpression of EDAG and no remission in de novo AML has been reported: this result suggests that EDAG may play a modulator role in AML and could be a new target in the treatment of AML. 6 A number of hematopoietic-specific transcription factors are found to regulate the molecular pathways of hematopoiesis through direct binding to regulatory elements of key hematopoietic genes. 7 For instance, GATA proteins bind to the consensus sequence WGATAR in the promoter regions of a variety of erythroid genes. 8 Members of the GATA family are generally categorized as hematopoietic GATA factors and cardiovascular GATA factors. 9 Among the former, GATA1 and GATA2 play critical roles in hematopoiesis, particularly erythropoiesis, whereas GATA3 is primarily involved in T-cell development. 10 To gain further insights into the regulatory mechanism(s) of Hemgn, we isolated and characterized a Hemgn promoter. In this report, we show that the Hemgn promoter exhibits hematopoietic-specific activities both in vitro and in vivo. Mutagenesis, gel shifting and chromatin immunoprecipitation (ChIP) analyses were used to demonstrate the transcriptionally important roles of the GATA boxes and their binding protein, GATA1, in the Hemgn 5 0 untranslated region (5 0 UTR). Finally, we report that expression of GATA1 and EDAG appear to be coregulated in primary AML cells.
Materials and methods

Hemgn promoter isolation and sequence analysis
A BAC clones (# 567P14) containing the full-length Hemgn gene was screened from a mouse BAC genomic library CITB-CJ7-B (Research Genetics, Catalogue # 96021) (for details, see Supplementary Information). A Hemgn promoter spanning 3171 bp (positions À2975 to þ 196) was amplified with pfu Turbo DNA polymerase (Stratagene, CA, USA) using the BAC as a template. The Hemgn promoter was confirmed by DNA sequencing. The sequence homology comparison of human and mouse Hemgn genes was performed using VISTA (http:// dcode.org) (Figure 1b) . 11 The sequences of mouse and human proximal promoters and the first exons were aligned using ClustalW (http://www2.ebi.ac.uk/clustalw). The MatInspector program (http://www.gene-regulation.com/) was used to identify putative hematopoietic-specific transcription factor binding sites in the sequence (Figure 1c ).
Cell culture, transfections, and reporter assays 10T1/2 (a mouse fibroblast cell line), PAC1 (a rat smooth muscle cell line), COS-7 (a monkey kidney cell line), C2C12 (a mouse skeletal muscle cell line) and K562 cells (a human erythroleukemia cell line) were co-transfected with indicated plasmids and 200 ng of pRL-SV40 Renilla Luciferase reporter (as an internal control). The culture condition and transfection conditions are detailed in Supplementary Information. Cells were harvested 24 h after transfection and luciferase activities were measured using Dual-Luciferaset reporter assay system (Promega, Madison, WI, USA). Drosophila Mel-2 cells (D. Mel-2, a Schneider S2 insect cell line) from Invitrogen (Carlsbad, CA, USA) were co-transfected with 1 mg of the Hemgn-luciferase reporter gene construct (pHemgn-2975 þ 196luc) and GATA1 (50-400 ng pPacGA-TA1) 12 using Fugenet 6 reagent (Roche Diagnostics Corporation, IN, USA). Cells were harvested after 24 h for luciferase assays using the Single Luciferase Assay System (Promega). Luciferase activities were normalized to total cell protein, measured by the Bio-Rad protein assay system. CMS, an acute myeloid leukemia cell line (established from a 2-year-old girl with acute megakaryocytic leukemia (AMkL)) 13 was a gift from Dr A Fuse (National Institute of Infectious Diseases, Tokyo, Japan). The AMkL cell line, Meg-01, was obtained from the American Type Culture Collection (Manassas, VA, USA).
14 Single colonies of CMS cells with stably transfected pcDNA3-GATA1 15 were screened for GATA1 expression by real time RT-PCR (for details see Supplementary Information).
Construction of Hemgn promoter deletion and mutant constructs
Deletion mutants of the Hemgn promoter were cloned into the luciferase reporter vector pXP1. 16 The constructs were verified by sequencing. The primers for amplifying the corresponding Hemgn promoter and its deletion mutants were: pHemgn The core GATA binding sequences in the plasmid pHemgn À2975 þ 196 luc construct were mutated to cATA, a change reported to abolish GATA binding, [17] [18] [19] using the Quickchanget site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The primer for GATA box1 mutation was: 5 0 -CCT CAC ACC TGT GCA GTG TcA TAA AGA AAG TGG. The primer for GATA box2 mutation was: 5 0 -GCT GTG GTC TAA CCA cAT AAA ACT TTT AGG CGG G. Double mutations of both boxes were also generated. The primer for GATA box3 mutation was: 5 0 -GTGTTGGTCTTaAgcTTTTCAA AAAGC. The mutant constructs (named as mut GATA box1 luc, mut GATA box2 luc, mut GA-TA box3 luc and mut GATA box1 þ 2 luc) were recloned into pXP1 vector (to eliminate possible mutation in the vector) and were verified by sequencing.
Generation and analysis of Hemgn promoter in transgenic mice
The Hemgn promoter (pHemgn À2975 þ 196 ) linked to a lacZ reporter was used to generate transgenic mice (Cold Spring Harbor Transgenic Core Facility). The transgenic mice were identified by PCR-genotyping using lacZ-specific primers.
RNAs from embryos and tissues were isolated using Trizol (Invitrogen) and the expression of the lacZ transgene was examined by RT-PCR using lacZ-specific primers. The lacZ expression was also detected by X-gal staining as detailed in Supplementary Information.
Gel shift and ChIP assays
The nuclear extracts (3 mg) from a mouse erythroleukemia cell line (MEL) (Active Motif, Carlsbad, CA, USA) were used in gel shift assays. The experimental procedures were described before. 20 The oligonucleotides used are as follows: GATAsite1:
For the competition studies, 100-fold molar excess of unlabeled oligonucleotide was included in the binding reaction. For supershift analysis, 2 mg anti-GATA1 or anti-GATA2 antibodies (Santa Cruz Biotechnology) were incubated with nuclear extracts respectively at room temperature for 20 min prior to their use in the binding reactions.
The ChIP assay was performed as described previously.
14 Purified chromatin fragments from Meg-01 (an AMkL cell line) were incubated with anti-GATA1 antibodies (C-20, Santa Cruz Inc.). Standard PCR for the HEMGN promoter region was performed using forward (5 0 -CCAGACACTTCCTGGCAGAT) and reverse (5 0 -CACTTGACTTCCCGCCTAAA) primers spanning positions -141 to þ 89. A coding region (exon 3) of the human GATA1 gene was also amplified using forward (5 0 -TGGAGA CTTTGAAGACAGAGCGGCTGAG) and reverse (5 0 -GAAGC TTGGGAGAGGAATAGGCTGCTGA) primers to validate the specificity of the ChIP assays.
Western blot analyses
The presence of GATA1 and GATA2 in MEL nuclear extracts was detected by Western blot assays using anti-GATA1 or anti-GATA2 antibodies (Santa Cruz Biotechnology), as described before. 21 Primary antibodies were detected with POD conjugated anti-goat-IgG and a BM Chemiluminescence Western Blotting kit (Roche).
Real time RT-PCR
Total RNAs were extracted from mock-transfected, and GATA1 stably transfected CMS cells or primary myeloblasts of newly diagnosed acute myeloid leukemia patients using TriReagent (Molecular Research Center Inc.). First strand cDNAs were prepared from 1 mg RNA using random hexamer primers and a RT-PCR kit (Perkin Elmer), and purified with the QIAquick PCR Purification Kit (Qiagen). GATA1, EDAG and 18S RNA transcript levels were quantitated using a LightCycler real-time PCR machine (Roche). The primer sequences and the real-time PCR condition are detailed in Supplementary Information. EDAG and GATA1 transcript levels were expressed relative to 18S RNA. Real-time PCR results were expressed as mean values from two to three experiments using the same cDNA preparation.
Clinical AML samples
Myeloblasts from children diagnosed with AML were obtained from the Children's Hospital of Michigan leukemia cell bank. Mononuclear cells were isolated on Ficoll-Hypaque gradients to obtain highly purified mononuclear cell fractions consisting mostly of leukemic blasts. Total RNAs were extracted from the samples using TRIzol reagent (Life Technologies). The research protocol was approved by the Human Investigation Committee of Wayne State University School of Medicine.
Statistical analysis
The nonparametric Spearman rank correlation coefficient was used to analyze HEMGN transcript levels and their relationship to GATA1 transcript levels. Statistical analyses were performed with StatView (Version 4.5, for Windows).
Results
Isolating mouse Hemgn promoters
Our previous studies characterized the temporospatial expression patterns of Hemgn in hematopoiesis. To investigate the underlying regulatory mechanisms, we examined the Hemgn promoters both in vitro and in vivo. Sequence analyses confirmed a BAC clone (#567P14) containing the Hemgn locus ( Figure 1a) . As demonstrated by the Vista plot (Figure 1b) , we compared sequences of mouse and human Hemgn genes. Although mouse and human Hemgn were highly conserved in the exons, there were few homologous regions in the introns. However, several evolutionarily conserved regions (ECRs) are located in the 5 0 UTR and 5 0 flanking sequence. These highly homologous regions contain potential regulatory elements that may control the Hemgn promoter activities.
The sequences of the highly homologous proximal promoters and the first exons of mouse and human Hemgn were aligned (Figure 1c) . The promoters contained a TATA box (TATAAA) that was conserved in mouse and human. In the search for the binding sites of hematopoietic transcription factors, two conserved GATA boxes, designated GATA box1 and GATA box2 , were identified in the 5 0 UTR that were exact matches to the consensus sequence WGATAR. 8 The GATA box3 has 1 bp mismatch with the consensus sequence. The presence of the GATA boxes were in the Hemgn 5 0 UTR was confirmed by RT-PCR using mRNA from mouse spleen and human K562 cells. A forward primer containing the GATA box1 and a reverse primer in exon 3 were used and the expected 897 and 607 bp amplicons were amplified from spleen and K562 cDNAs, respectively (data not shown). This establishes that GATA boxes are located in the 5 0 UTR of both mouse and human Hemgn mRNAs.
The Hemgn promoter is specifically transactivated in a hematopoietic cell line
To investigate the regulatory mechanisms of Hemgn expression during hematopoiesis, we isolated a putative Hemgn promoter that contained 2975 bp of 5 0 upstream sequence and 196 bp of the 5 0 UTR. To determine whether this region was sufficient to activate Hemgn transcription, we generated a plasmid pHemgn À2975 þ 196 luc in which the luciferase reporter was driven by the Hemgn promoter. When transfected into an erythroleukemic cell line (K562), the pHemgn À2975 þ 196 promoter was sufficient to activate the transcription of the luciferase reporter (Figure 2 ). This promoter construct showed much lower transactivation activities in nonhematopoietic cells including 10T1/2 (a fibroblast cell line), PAC1 (a smooth muscle cell line), COS-7 (a kidney cell line) and C2C12 (a skeletal muscle cell line) (Figure 2 (Figure 2 ). These results demonstrate that the Hemgn promoters are selectively activated in hematopoietic cells in vitro.
The Hemgn promoter is activated in hematopoietic tissues in vivo To determine whether the Hemgn promoter is sufficient to activate transcription in vivo, we examined the expression of a lacZ transgene driven by the pHemgn À2975 þ 196 promoter in transgenic mice. Given that the endogenous Hemgn is specifically expressed in hematopoietic tissues during hematopoiesis, we examined the transgene expression in hematopoietic tissues from fetal and adult tissues. We generated seven independent transgenic founders that show similar expression pattern of transgene. One of the representative transgenic mouse lines is described here. We demonstrated that the pHemgn À2975 þ 196 promoter was sufficient to activate the transcription of lacZ transgene in the yolk sac and fetal liver during embryogenesis (Figure 3A and B) . In the adults, we also detected the lacZ transgene expression in hematopoietic tissues including spleen and bone marrow, but not in nonhematopoietic tissues such as heart, liver, kidney and skeletal muscle ( Figure 3A) . However, the expression of the lacZ transgene was also unexpectedly detected in the brain, thymus, lung and testis ( Figure 3A) .
Histological analyses demonstrated that the lacZ staining was present in adult bone marrow cells (indicated by yellow arrow, Figure 3B-a,b) . In adult spleen, the lacZ staining was localized in the red pulp (RP), which is active in erythropoiesis ( Figure 3B-c,d) . The x-gal staining was also observed in the hematopoietic islands (yellow arrow) of the fetal liver (E13.5) ( Figure 3B-e,f) . These results demonstrate that the pHemgn À2975 þ 196 promoter contains critical regulatory elements for Hemgn expression in hematopoietic tissues in vivo.
Functional analysis of GATA binding elements in the Hemgn promoter
To identify the regulatory elements for Hemgn promoter, we generated deletion mutants of the Hemgn promoter using pHemgn À2975 þ 196 luc as a template (Figure 4) . The wild-type Figure 2 The Hemgn promoter is specifically expressed in hematopoietic cells in vitro. The luciferase reporter driven by indicated Hemgn promoter or the promoter-less vector was transfected into both hematopoietic (K562) and nonhematopoietic (PAC1, COS7, C 2 C 12 and 10T1/2) cell lines. The data are expressed as the fold increased activity of pHemgn À2975 þ 196 luc and pHemgn À831 þ 196 luc versus the promoter-less reporter vector pXP1. All transfection experiments were performed at least three times in triplicate. The relative luciferase activity was the mean7s.e.m. of these experiments. and mutated promoters were transfected into K562 cells and the transactivation activity of each promoter was compared with that of the promoterless reporter. The pHemgn À2975 þ 196 promoter activated the reporter 80-fold over the basal activity of the promoterless vector (pXp1). The pHemgn À831 þ 196 construct did not show significant reduction in promoter activity, whereas the pHemgn À404 þ 196 promoter showed a 40% decrease in the activity (Figure 4a) . Remarkably, when the 184 bp sequence in the 5 0 UTR was deleted from the pHemgn À2975 þ 196 promoter, the activity of the resulting pHemgn À2975 þ 12 promoter construct was reduced to the basal level, indicating that the 184 bp DNA fragment contains critical regulatory elements (Figure 4a ).
As shown in Figure 1c , the deleted 184 bp sequence contains three GATA boxes. Given the established roles of GATA factors in hematopoietic gene regulation, it seemed likely that the GATA boxes in the 5 0 UTR are critical for Hemgn transactivation. Since previous studies have shown that the G in the GATA core sequence is critical for the binding of GATA factors, [22] [23] [24] the sequence was mutated to a/cATA to abolish GATA binding activity. [17] [18] [19] Indeed, in our analysis mutation of the GATA box1 or GATA box2 sites suppressed promoter activity in K562 cells by about 95 and 90%, respectively (Figure 4b ). Mutation at both GATA boxes completely eliminated the promoter activity (Figure 4b ). However, mutation at GATA box3 did not affect the promoter activities (Figure 4b ). These results strongly suggest that both GATA box1 and GATA box2 are essential for high-level Hemgn promoter activity in hematopoietic cells.
GATA1, not GATA2, binds and transactivates the Hemgn promoter
Since GATA3 is predominantly expressed in lymphoid lineages, GATA1 and GATA2 would seem to be the possible regulators for Hemgn, via binding to the GATA box1 and GATA box2 sites in the 5 0 UTR. To directly assess whether GATA1 and GATA2 can bind to the Hemgn promoter, we performed electrophoretic mobility shift assays using nuclear extracts from a mouse erythroleukemia cell line, MEL, and a DNA oligo containing either the GATA box1 or the GATA box2 as a probe. This analysis demonstrated that two protein complexes bound to both GATA box1 and GATA box2 probes (Figure 5a ). The faster migrating complex could be specifically competed away by excess (100 Â ) wild type (i.e., GATA box1 , GATA box2 ) oligos and the consensus GATA box oligo, but not the GATA box1 and GATA box2 oligos including the identical mutations in the reporter gene assays (Figure 5a ). Moreover, anti-GATA1 antibody disrupted the binding of this complex to both GATA box1 and GATA box2 . However, the anti-GATA2 antibody failed to disrupt the binding complex (Figure 5a ). Although the slower migrating complex could be specifically competed away unlabeled wild type oligos, the consensus GATA box oligo and the anti-GATA antibodies had no effect on this DNA-protein complex, indicating its association with DNA binding proteins other than GATA. Western blot analysis confirms that both GATA1 and GATA2 proteins are present in MEL nuclear extracts (Figure 5b ). This study establishes that GATA1, but not GATA2, in MEL nuclear extracts binds to the GATA box1 and GATA box2 elements in the Hemgn promoter.
In vivo binding of GATA1 to the HEMGN promoter was confirmed by ChIP assays using primers flanking the proximal HEMGN promoter and the GATA1 antibodies-precipitated chromatin fragments from Meg-01 cells. The binding of GATA1 is only detected in anti-GATA1-precipitated chromatin fragments, and not in nonspecific IgG precipitated chromatin fragments (Figure 5c ). We also used the primers located in the coding region (exon 3) of the GATA1 gene to confirm the specificity of the precipitation: GATA1 fails to immunoprecipitate the exon 3 (the coding region) of the GATA1 gene (Figure 5c ). This result demonstrates that GATA1 binds to the proximal promoter of the HEMGN promoter in the context of chromatin.
To assess directly the role of GATA1 protein in Hemgn transactivation, GATA1 cDNA in pPac vector was co-transfected with the wild-type or the double GATA-box mutant Hemgn promoter into D. Mel-2 cells in which GATA1 promoter is not detected. Therefore, both the wild-type and the mutant Hemgn promoters show basal luciferase activities in the absence of GATA1 co-transfection. GATA1 transactivated the wild-type Hemgn promoter (pHemgn À2975 þ 196 ) in a dose-dependent manner; however, it failed to transactivate the mutant Hemgn promoter p mut GATA box1 þ 2 Hemgn À2975 þ 196 (Figure 5d ). These results suggest that GATA1 is a key transcription factor that binds and transactivates the Hemgn promoter.
Increasing the endogenous HEMGN transcripts by GATA1 in CMS cells
The effect of GATA1 on the endogenous HEMGN promoter was assessed by overexpressing GATA1 in CMS cells (an AML cell line) and determining changes in levels of endogenous EDAG transcripts. EDAG transcripts were measured by real time RT-PCR and normalized to 18S rRNA. Accordingly, expression of GATA1 increased levels of endogenous EDAG transcripts (Figure 6a and b) . These results suggest that exogenous GATA1 is sufficient to transactivate the endogenous HEMGN promoter.
Correlation between EDAG and GATA1 transcripts in acute myeloid leukemia patient samples A recent study reported that EDAG is highly expressed in myeloblasts from acute myeloid leukemia patients. 6 To further confirm that EDAG is a downstream target of GATA1, we performed the real time RT-PCR to quantify EDAG and GATA1 transcript levels in primary myeloblast specimens. As shown in Figure 6c , both EDAG and GATA1 transcripts varied over a substantial range (for EDAG: 0.06 to 19.85 with a mean of 0.6325; for GATA1: 0.016 to 3.988 with a mean of 0.1350). Importantly, EDAG transcripts significantly correlated with the GATA1 transcript levels (r ¼ 0.93, p ¼ 0.0003). This result strongly supports a regulatory role of GATA1 in EDAG transcription in AML.
Discussion
Our previous studies demonstrate that Hemgn is highly expressed in hematopoietic stem/progenitor cells during hematopoiesis. 1 In this report, we examined the regulation of Hemgn expression both in vitro and in vivo. We isolated a Hemgn promoter that contained 2975 bp of upstream flanking DNA sequence and 196 bp of 5 0 UTR sequence. This promoter was preferentially expressed in a cultured hematopoietic cell line and hematopoietic tissues in transgenic mice. Mutagenesis studies demonstrated that two GATA boxes in the 5 0 UTR were required for promoter transactivation. GATA1, but not GATA2, in nuclear extracts prepared from a mouse erythroleukemia cell line (MEL) bound the Hemgn promoter at these GATA binding sites.
The expression profiles of hemogen in mice, humans and rats are highly enriched in hematopoietic tissues. [1] [2] [3] Recently, we reported a distinct Hemgn mRNA isoform in round spermatids of the testis. 21 However, transcription of this testicular mRNA isoform is driven by an alternative promoter located at 6 kb upstream of the hematopoietic promoter. 21 Consistent with these studies, the Hemgn promoter (pHemgn À2975 þ 196 ) is predominantly expressed in hematopoietic tissues (Figure 3) . Therefore, it is likely that the Hemgn promoter tested in transgenic mice contains the critical regulatory elements necessary for Hemgn expression in hematopoietic tissues. Although the pHemgn À2975 þ 196 promoter is preferentially expressed in hematopoietic tissues in vivo, promoter activities were much lower than expected since the X-gal staining detected in the transgenic mice become apparent only after overnight staining (Figure 3) . These results suggest that enhancer-like regulatory elements may exist beyond the 3171 bp promoter region described herein. We also detected ectopic expression of the Hemgn transgene in the brain, thymus, lung and testis by RT-PCR. This implies that additional regulatory elements are required to ensure the repression of the endogenous Hemgn in thymus and nonhematopoietic tissues.
Although GATA elements appear to be essential in determining the transactivation of the Hemgn promoter, it does not exclude the possibility of an involvement of other regulatory elements. According to current models, GATA factors are central mediators for hematopoietic gene regulation. 25 Therefore, it is very likely that GATA box binding factors regulate Hemgn expression by recruiting other hematopoietic regulators that bind directly or indirectly to the Hemgn promoter. We have found a cluster of evolutionarily conserved regulatory boxes for hematopoietic regulators in the Hemogen upstream region such as AML-1, Evi-I and Ets (Figure 1c) . Studies are underway to further explore the possible molecular interactions between GATA factors and other hematopoietic regulators in regulating Hemgn transcription. It will be of particular interest to establish the extent to which GATA protein binding within the 5 0 UTR interacts with the upstream basal transcriptional machinery (e.g., TATA box) to modulate Hemgn transcription. We envisage that a dynamic process of binding and dissociation of GATA factors is involved in transcriptional initiation and elongation of the Hemgn gene.
Since both GATA1 and GATA2 bind to the consensus DNA sequence WGATAR that is present in promoters of a number of hematopoietic genes, 25 it is not fully understood how these GATA family members distinguish different DNA sequences to regulate different genes. Previous studies have revealed some variations in DNA binding specificities among different GATA factors. For instance, the N-terminal zinc fingers of GATA1, GATA2 and GATA3 recognize different DNA motifs and may contribute to their selectivity in binding target DNA sites. 26 Extensive studies using both in vitro and in vivo models demonstrate that the functions and downstream targets of GATA1 overlap with those of GATA2. 25, 27, 28 Moreover, in GATA1 knockout mice, GATA2 is upregulated to partially compensate for the loss of GATA1, and both GATA1 and GATA2 are critical for initiation of blood formation.
28,29 In this report, we investigated the potential roles of GATA1 and GATA2 in regulating Hemgn transcription. We found that only GATA1 can bind and transactivate the Hemgn promoter. Consistent with this observation, the expression level of EDAG closely correlated with that of GATA1 in human leukemiaderived cell lines and primary AML specimens ( Figure 6 ). Although GATA1 and GATA2 bind to the same consensus nucleotides, flanking sequences may further influence their binding preferences. The differential binding observed in our EMSA assay could be due to the binding affinity difference of GATA1 versus GATA2 to the Hemgn promoter. It remains to be investigated whether and how GATA2 is involved in the expression of Hemgn in vivo. This question will be addressed using GATA1 and GATA2 knockout mice.
In conclusion, we provide evidence to show that Hemgn is a direct transcriptional target of GATA1, a key regulator of erythropoiesis. GATA1 deficient mice die during early embryogenesis from severe anemia with erythroid differentiation arrested at the proerythroblast stage and rapid apoptosis of these cells , 29 suggesting a role of GATA1 in erythroid cell survival and maturation. Hemgn also appears to play a key role in erythropoiesis. Overexpression of EDAG (the Hemgn human ortholog) results in resistance of cell apoptosis, and expression of EDAG in K562 cells promotes the cell growth and inhibits erythroid differentiation, 4 which is consistent with the expression of Hemgn in erythroblasts 1 and the downregulation during erythroid differentiation. 2 Hemgn may thus play a positive role in cell survival and a negative role in erythroid terminal differentiation. The molecular mechanism by which Hemgn exerts its biological function remains unknown, however, a putative coiled-coil motif in its N-terminus suggests this protein may dimerize or bind with other proteins. 1 Further experiments are warranted to investigate how hemgn interacts with other nuclear factors such as EKLF and GATA1 in the regulation of erythroid development.
A recent study has reported an inverse relationship between HEMGN/EDAG expression and the chemotherapy response for AML patients 6 and our own results strongly suggest a causal relationship between GATA1 and EDAG in primary AMLs. Since mutation of GATA1 has been shown to contribute to the chemotherapy sensitivity of AML in Down's syndrome patients, 12 it is conceivable that the downregulation of HEMGN may be involved in molecular mechanisms of the remarkable chemotherapy sensitivity of this unique group of AML patients.
